Table 2.
Nanomedicines in clinical trials for treating advanced-stage cancers. The targeting strategy for all cases in passive.
| Name (Active Drug) | Carrier | Cancer Type | Clinical Status | Reference |
|---|---|---|---|---|
| Caelyx (doxorubicin) | liposome | Metastatic breast cancer/advanced ovarian cancer | Approved | [10] |
| NK-105 (paclitaxel) | Polymeric micelle | Metastatic breast cancer | Phase III | [12] |
| EndoTAG-1 (paclitaxel) | Liposome | Metastatic triple-negative breast cancer | Phase III | [13] |
| ABI-009 (rapamycin) | Albumin NP | Advanced sarcoma | Phase II | [14] |
| CRLX-101 (camptothecin) | Polymeric NP | Advanced renal carcinoma | Phase II | [15] |
| CPX-1 (Irinotecan HCl:Floxuridine) | Liposome | Advanced colorectal cancer | Phase II | [16] |
| SGT53 (p53 cDNA) | Liposome | Metastatic pancreatic cancer | Phase II | [17] |
| DepoVax (tumor antigen) | Liposome | Advance-staged breast, prostate, and ovarian cancers | Phase I | [18] |